Holen Sie sich die Stockscreener-App
135.56
0.40%
-0.55
Handel nachbörslich:
135.56
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTGX|Protagonist Therapeutics Inc|Price:136.110|Chg%:+0.680 - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protagonist Therapeutics, Inc. Revenue Breakdown – NASDAQ:PTGX - TradingView
TradingKey - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
PTGX Pulls Back: Protagonist Therapeutics Holds Above Support After Modest DeclineDealer Gamma - dars.gov.et
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
PROTAGONIST THERAPEUTICS INC : JEFFERIES RAISES TARGET PRICE TO $172 FROM $121 - Bitget
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup - ChartMill
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com - Investing.com Australia
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
PROTAGONIST THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $155 FROM $100 - Bitget
Protagonist Therapeutics stock hits all-time high at 141.79 USD - Investing.com
Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Protagonist Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - Sahm
Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com - Investing.com Canada
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan - Stock Titan
Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight - AlphaStreet
Protagonist Therapeutics Is Maintained at Overweight by Barclays - Moomoo
PTGX Maintained by Barclays -- Price Target Raised to $151 - GuruFocus
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Best Momentum Stocks to Buy for July 13th - Yahoo Finance Singapore
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics Inc. (PTGX) Q1 2026 Earnings: Surprise Profitability Defies Estimates, Yet Shares SlideEPS Consistency Score - dars.gov.et
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) - The Globe and Mail
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $145 - Moomoo
PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com
Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView
Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating - Moomoo
Enterprise value to revenue forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView
Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD - Investing.com
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):